Cumberland (CPIX) VP awarded options to buy 3,000 shares at $2.80

Rhea-AI Filing Summary

Bitterman Chris T. reported acquisition or exercise transactions in this Form 4 filing.

Cumberland Pharmaceuticals vice president of sales and marketing Chris T. Bitterman received a grant of options to buy 3,000 shares of common stock at $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 16, 2036. Following this award, he holds options covering 19,000 shares in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bitterman Chris T.

Role Vice Pres Sales & Marketing

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	3,000	$2.80	$8K

Holdings After Transaction: Options (right to buy) — 19,000 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bitterman Chris T.

(Last) (First) (Middle)

1600 WEST END AVE.

SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice Pres Sales & Marketing

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$2.8	03/18/2026		A		3,000		03/18/2030	03/16/2036	Common Stock	3,000	$2.8	19,000	D

Explanation of Responses:

Remarks:

	Chris T. Bitterman by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CPIX report for Chris T. Bitterman?

Chris T. Bitterman received a stock option grant for 3,000 shares. The options allow him to buy Cumberland Pharmaceuticals common stock at $2.80 per share, reflecting routine equity-based compensation for his role as vice president of sales and marketing.

What are the key terms of Chris T. Bitterman’s CPIX stock options?

The options cover 3,000 shares at an exercise price of $2.80. They become exercisable on March 18, 2030 and expire on March 16, 2036, giving him a defined window to purchase Cumberland Pharmaceuticals common shares.

How many Cumberland Pharmaceuticals options does Chris T. Bitterman hold after this grant?

After the grant, Chris T. Bitterman holds options on 19,000 shares. The Form 4 shows his total derivative holdings following the transaction, indicating cumulative options to acquire Cumberland Pharmaceuticals common stock, including the newly awarded 3,000-share grant.

Is the CPIX Form 4 transaction an open-market buy or a compensation grant?

The CPIX Form 4 reflects a compensation-related option grant, not an open-market purchase. The transaction is coded “A” for a grant, award, or other acquisition and represents equity compensation granted by the company to the executive.

What role does Chris T. Bitterman hold at Cumberland Pharmaceuticals (CPIX)?

Chris T. Bitterman serves as vice president of sales and marketing at Cumberland Pharmaceuticals. His Form 4 filing discloses equity compensation in the form of stock options granted in connection with his executive position at the company.